Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11519)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 19, 2021 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Psychiatry
ISSN
2220-3206
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J Psychiatr 2021; 11(8): 429-448 [PMID: 34513606 DOI: 10.5498/wjp.v11.i8.429] |
|---|---|
| URL: | https://www.wjgnet.com/2220-3206/full/v11/i8/429.htm |
| Number | Citing Articles |
| 1 |
Martina Nováková, Tomáš Hammer, Eliška Nováková, Michaela Mayerová, Libor Ustohal, Hana Kotolová. Možnost ovlivnění duševního zdraví u pacientů s farmakorezistentní schizofrení – augmentace klozapinu dlouhodobě působícími parenterálními antipsychotiky: série případů. Česká a slovenská farmacie 2023; 72(6): 276 doi: 10.5817/CSF2023-6-276
|
| 2 |
Irina Vladimirovna Dubatova, Lema Andreevich Antsyborov, Artur Fedorovich Kheigetian, Andrey Viktorovich Antsyborov. “Golden Shot” in the Treatment and Diagnosis of Schizophrenia: Psychiatrists or Neuroscientists?. Interactive science 2021; (10 (65)): 9 doi: 10.21661/r-555399
|
| 3 |
Marcin Siwek, Adrian Andrzej Chrobak, Aleksandra Gorostowicz, Patrycja Król, Dominika Dudek. Cariprazine augmentation of clozapine in schizophrenia—a retrospective chart review. Frontiers in Pharmacology 2024; 14 doi: 10.3389/fphar.2023.1321112
|
| 4 |
Ping-Tao Tseng, Mu-Hong Chen, Chih-Sung Liang. Difference between treatment-resistant schizophrenia and clozapine-resistant schizophrenia. World Journal of Psychiatry 2022; 12(8): 1102-1104 doi: 10.5498/wjp.v12.i8.1102
|
| 5 |
Laura Orsolini, Silvia Bellagamba, Virginio Salvi, Umberto Volpe. A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy. Asian Journal of Psychiatry 2022; 72: 103121 doi: 10.1016/j.ajp.2022.103121
|
| 6 |
Phillipa Louise Brothwood, Mina Husain, Jessica Pinson, Ebenezer Oloyede, Patrick Davey, Eromona Whiskey. Clozapine in Combination With Olanzapine Long-Acting Injection. Journal of Clinical Psychopharmacology 2023; 43(5): 472 doi: 10.1097/JCP.0000000000001746
|
| 7 |
Djenifer B. Kappel, Sophie E. Legge, Leon Hubbard, Isabella R. Willcocks, Kevin S. O’Connell, Robert L. Smith, Espen Molden, Ole A. Andreassen, Adrian King, John Jansen, Marinka Helthuis, Michael J. Owen, Michael C. O’Donovan, James T.R. Walters, Antonio F. Pardiñas. Genomic Stratification of Clozapine Prescription Patterns Using Schizophrenia Polygenic Scores. Biological Psychiatry 2023; 93(2): 149 doi: 10.1016/j.biopsych.2022.07.014
|
| 8 |
Asmaa Fady Sharif, Zahraa Khalifa Sobh, Sanaa Abd El-Fatah Abdo, Osama M. Alahmadi, Hatem A. Alharbi, Mohannad Saif Awaji, Faris A. Alabdullatif, Abdullah M. Baghlaf, Ahmad F. Alanazi, Manar Maher Fayed. Evaluation of Global Dystonia Rating Scale as a predictor of unfavorable outcomes among acute antipsychotics poisoned patients. Drug and Chemical Toxicology 2024; 47(4): 386 doi: 10.1080/01480545.2024.2313561
|
| 9 |
Alexandre Hudon, Kingsada Phraxayavong, Stéphane Potvin, Alexandre Dumais. Ensemble Methods to Optimize Automated Text Classification in Avatar Therapy. BioMedInformatics 2024; 4(1): 423 doi: 10.3390/biomedinformatics4010024
|
| 10 |
Soumitra Das, Annie Itrat, Mary Elizabeth Trejo Hernandez, Rasish Subedi, Thusanth Jogarajah, Sreshatha Vashist, Nikitha Daggala. Clozapine-induced eosinophilia: A case report. SAGE Open Medical Case Reports 2023; 11 doi: 10.1177/2050313X231195961
|
| 11 |
Marina Youykheang, Zaki Al Hallaq, Kenny Menelas, Robert S. Biskin, Vincent Dagenais-Beaulé. Combination of Long-Acting Injectable Antipsychotics in the Treatment of Psychiatric Disorders—A Systematic Review of the Literature and Case Series. Journal of Clinical Psychopharmacology 2023; 43(1): 20 doi: 10.1097/JCP.0000000000001627
|
| 12 |
Sandeep Grover, Sanjana Kathiravan. Clozapine research from India: A systematic review. Asian Journal of Psychiatry 2023; 79: 103353 doi: 10.1016/j.ajp.2022.103353
|
| 13 |
Inmaculada Baeza, Adriana Fortea, Daniel Ilzarbe, Gisela Sugranyes. What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review. Pediatric Drugs 2023; 25(2): 135 doi: 10.1007/s40272-023-00558-x
|
| 14 |
Ta-Chun Lin, Ching-Hua Lin. Schizophrenia Patients Discharged on Clozapine Plus Long-Acting Injectable Antipsychotics From a Public Psychiatric Hospital in Taiwan, 2006–2021. International Journal of Neuropsychopharmacology 2023; 26(11): 808 doi: 10.1093/ijnp/pyad053
|
| 15 |
Pierre-Michel Llorca, Philippe Nuss, Éric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, Stéphane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-Noëlle Vacheron, Jean-Michel Azorin. Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC Psychiatry 2022; 22(1) doi: 10.1186/s12888-022-04008-9
|
| 16 |
Marcin Siwek, Adrian Andrzej Chrobak, Aleksandra Gorostowicz, Patrycja Król, Dominika Dudek. Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review. Brain Sciences 2023; 13(3): 445 doi: 10.3390/brainsci13030445
|
| 17 |
Zijin Feng, Zhijing Hu, Lei Li, Minquan Yu, Yiting Zhang, Peng Jing, Xiangqing Xu, Jinhui Wu, Yiqiao Hu, Xiangyang Xu. Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1298061
|
| 18 |
Sumaila Asif, Jigyansa Ipsita Pattnaik, Ipsita Debata, Sudipta Kumar Das, Jayaprakash Russell Ravan, Swayanka Samantaray, Ramakant Swain. Predictors of clozapine efficacy in treatment-resistant schizophrenia: A cross-sectional analysis of sociodemographic, clinical, biochemical, and electrophysiological EEG changes. Archives of Mental Health 2024; doi: 10.4103/amh.amh_188_23
|
| 19 |
Archana Mishra, Rituparna Maiti, Mathan kumar Ramasubbu, Anand Srinivasan. Evaluation of the pharmacodynamic interaction effect of augmentation agents with clozapine in patients with treatment-resistant schizophrenia: A simulation study of clinical data. Psychiatry Research 2024; 338: 115989 doi: 10.1016/j.psychres.2024.115989
|
| 20 |
Noora Tuovinen, Alex Hofer. Resting-state functional MRI in treatment-resistant schizophrenia. Frontiers in Neuroimaging 2023; 2 doi: 10.3389/fnimg.2023.1127508
|
| 21 |
Tanya Paul, Jia Whei See, Vetrivel Vijayakumar, Temiloluwa Njideaka-Kevin, Hanyou Loh, Vivian Jia Qi Lee, Bekir Nihat Dogrul. Neurostructural changes in schizophrenia and treatment-resistance: a narrative review. Psychoradiology 2024; 4 doi: 10.1093/psyrad/kkae015
|
| 22 |
Vjekoslav Peitl, Antonia Puljić, Mislav Škrobo, Sergej Nadalin, Lidija Fumić Dunkić, Dalibor Karlović. Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia. Biomedicines 2023; 11(4): 1072 doi: 10.3390/biomedicines11041072
|
| 23 |
Jae Hee Cho, Hindol Mukherjee, Vladimir Sazhin. Is antipsychotic augmentation associated with improved functioning in patients on clozapine?. Australasian Psychiatry 2024; 32(3): 186 doi: 10.1177/10398562241232819
|
| 24 |
Pasindu Wickramarachchi, Jessica M. Boyd, Dennis J. Orton. Biological variation in clozapine and metabolite reporting during therapeutic drug monitoring. Clinica Chimica Acta 2022; 531: 183 doi: 10.1016/j.cca.2022.04.005
|
| 25 |
Alexandre Hudon, Mélissa Beaudoin, Kingsada Phraxayavong, Stéphane Potvin, Alexandre Dumais. Enhancing Predictive Power: Integrating a Linear Support Vector Classifier with Logistic Regression for Patient Outcome Prognosis in Virtual Reality Therapy for Treatment-Resistant Schizophrenia. Journal of Personalized Medicine 2023; 13(12): 1660 doi: 10.3390/jpm13121660
|
| 26 |
Octavian Vasiliu. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?. Frontiers in Psychiatry 2022; 13 doi: 10.3389/fpsyt.2022.1069432
|
| 27 |
Sumeet Gupta, Samuel Mammolotti Parkinson. Management of sedation due to clozapine. BJPsych Advances 2023; 29(4): 283 doi: 10.1192/bja.2022.27
|
| 28 |
Carol Lim, Abigail L Donovan. Treatment paradigms for treatment-resistant schizophrenia. The Lancet Psychiatry 2024; 11(7): 488 doi: 10.1016/S2215-0366(24)00173-1
|
| 29 |
Andrea de Bartolomeis, Mariateresa Ciccarelli, Licia Vellucci, Michele Fornaro, Felice Iasevoli, Annarita Barone. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia. Expert Opinion on Pharmacotherapy 2022; 23(18): 2035 doi: 10.1080/14656566.2022.2145884
|
| 30 |
Federica Tralongo, Céline Konecki, Catherine Feliu, Arthur Kaladjian, Zoubir Djerada. Association Between Clozapine Plasma Concentrations and Treatment Response: A Systematic Review, Meta-analysis and Individual Participant Data Meta-analysis. Clinical Pharmacokinetics 2023; 62(6): 807 doi: 10.1007/s40262-023-01247-1
|
| 31 |
Ravi Philip Rajkumar. The Advantages of Combining Therapies in Treating Psychiatric Patients. Brain Sciences 2024; 14(7): 708 doi: 10.3390/brainsci14070708
|